Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CMVLF)
OTHER OTC:CMVLF
Ucart22, Clls52
B-Cell Acute Lymphoblastic Leukemia
Phase I/II
Recruiting
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Nov 01, 2019
―
Ucartcs1a
Relapsed/Refractory Multiple Myeloma
Phase I
Terminated
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Oct 25, 2019
―
Ucart123
Acute Myeloid Leukaemia
Phase I
Withdrawn
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
Sep 25, 2019
―
Ucart123
Blastic Plasmacytoid Dendritic Cell Neoplasm (Bpdcn)
Phase I
Terminated
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
Jun 14, 2017
―
Ucart123v1.2
Relapsed/Refractory Acute Myeloid Leukemia
Phase I
Active Not Recruiting
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Jun 14, 2017
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cellectis SA (CMVLF) have in its pipeline
CMVLF is currently developing the following drugs: Clls52, Ucart20x22, Ucart22, Clls52, Ucartcs1a. These drug candidates are in various stages of clinical development as the company works toward FDA approval.